Potential biomarkers with prognostic significance or predicting efficacy of anti-PD-1 ICIs for ESCC, such as tumor mutational burden, T-receptor clonality and molecular tumor burden index from peripheral blood, and tumor-infiltrating lymphocytes (TILs), are under active investigation (7–10). The gene discussed is PDCD1; the disease is neoplasm.